Press Releases

85_IGC-Pharma-to-Participate-in-Fireside-Chat-with-Ascendiant-Capital-Marketspsb
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets 
Read More →
83_Announces-Equity-Research-Update-by-Alliance-Global-Partners
IGC Pharma Announces Equity Research Update by Alliance Global Partners 
Read More →
83_Expands-Phase-2-CALMA-Trial-into-Colombia-with-Leading-Alzheimer's-Research-Center
IGC Pharma Expands Phase 2 CALMA Trial into Colombia’s Premier Alzheimer’s Research Center 
Read More →
82_IGC-Pharma-Reports-70%-Patient-Enrollment-Milestone-in-Phase-2-CALMA-Alzheimer’s-Agitation-Trial- (1)
IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer’s Agitation 
Read More →
81_IGC-Pharma-Expands-Phase-2-CALMA-Trial-with-New-Clinical-Trail-Site-at-Integrative-Clinical-Trials-in-New-York_
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trail Site at Integrative Clinical Trials in New York 
Read More →
80_IGC-Pharma-Expands-Phase-2-CALMA-Trial-with-New-Clinical-Site-at-Dominion-Medical
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship network site, in Richmond, Virginia 
Read More →
79_IGC-Pharma-Aligns-Fiscal-Year-with-Calendar-Year-to-Enhance-U.S.-Investor-Comparability
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability 
Read More →
78_IGC-Pharma-Raises-Capital-to-Advance-IGC-AD1-Phase-2-Trial-and-AI-Platform
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial 
Read More →
77_IGC-Pharma-Secures-New-U.S.-Patent-as-Pharmaceutical-Cannabinoids-Gain-Regulatory-Momentum-
IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum  
Read More →
76_-IGC-Pharma-Highlights-Strengthened-Strategic-Position-Amid-U.S.-Hemp-Regulatory-Shifts
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines 
Read More →
75_IGC-Pharma-Announces-Coverage-Report-by-Ascendiant-Capital-Markets-about-the-“Reports-Q2-results
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75.”
Read More →
74_-IGC-Pharma-Reports-65%-Patient-Enrollment-Milestone-in-Phase-2-CALMA-Alzheimer’s-Agitation-Trial
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer’s Agitation Trial 
Read More →
73_-IGC-Pharma-Announces-Activation-of-New-Clinical-Trial-Site
IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer’s Disease
Read More →
72_IGC-Pharma-Leverages-MINT-AD-to-Identify-Socioeconomic-Risk-Factors-Driving-Alzheimer's-and-Aging-Trends-2
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer’s and Aging Trends
Read More →
71_IGC-Pharma-Reports-Accelerated-Q2
IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital
Read More →
70_USPTO-Grants-IGC-Pharma-Patent-Rights-for-Novel-Composition-Targeting-Alzheimer’s-Disease-and-Central-Nervous-System-Disorders
USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer’s Disease and Central Nervous System Disorders
Read More →